Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Phage Display to Detect and Identify Autoantibodies in Disease.

Deutscher S.

N Engl J Med. 2019 Jul 4;381(1):89-91. doi: 10.1056/NEJMcibr1903249. No abstract available.

PMID:
31269373
2.

Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.

Peng Y, Prater AR, Deutscher SL.

Oncotarget. 2017 Sep 30;8(49):86747-86768. doi: 10.18632/oncotarget.21421. eCollection 2017 Oct 17.

3.

Characterization of In Vivo Selected Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications.

Newton-Northup J, Deutscher SL.

Methods Mol Biol. 2017;1572:445-465. doi: 10.1007/978-1-4939-6911-1_29.

PMID:
28299705
4.

Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.

Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, Cabral P, Cerecetto H.

Bioorg Med Chem. 2017 Feb 1;25(3):1163-1171. doi: 10.1016/j.bmc.2016.12.026. Epub 2016 Dec 24.

PMID:
28089349
5.

Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.

Northup JR, Deutscher SL.

Comb Chem High Throughput Screen. 2016;19(5):370-7.

PMID:
27055748
6.

Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2.

Larimer BM, Quinn JM, Kramer K, Komissarov A, Deutscher SL.

Int J Pept Res Ther. 2015 Dec 1;21(4):383-392. Epub 2015 May 9.

8.

In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging.

Soendergaard M, Newton-Northup JR, Deutscher SL.

Comb Chem High Throughput Screen. 2014;17(10):859-67.

PMID:
25360673
9.

In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.

Soendergaard M, Newton-Northup JR, Deutscher SL.

Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):561-70. eCollection 2014.

10.

Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.

Larimer BM, Deutscher SL.

Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):435-47. eCollection 2014.

11.

In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.

Newton-Northup JR, Dickerson MT, Kumar SR, Smith GP, Quinn TP, Deutscher SL.

Mol Imaging Biol. 2014 Dec;16(6):854-64. doi: 10.1007/s11307-014-0762-z.

PMID:
25001195
12.

Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.

Larimer BM, Thomas WD, Smith GP, Deutscher SL.

Mol Imaging Biol. 2014 Aug;16(4):449-58. doi: 10.1007/s11307-014-0724-5.

PMID:
24550054
13.

A blood based 12-miRNA signature of Alzheimer disease patients.

Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A.

Genome Biol. 2013 Jul 29;14(7):R78. doi: 10.1186/gb-2013-14-7-r78.

14.

Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11.

Tessier MB, Grant OC, Heimburg-Molinaro J, Smith D, Jadey S, Gulick AM, Glushka J, Deutscher SL, Rittenhouse-Olson K, Woods RJ.

PLoS One. 2013;8(1):e54874. doi: 10.1371/journal.pone.0054874. Epub 2013 Jan 24.

15.

Nanoparticles and phage display selected peptides for imaging and therapy of cancer.

Cutler CS, Chanda N, Shukla R, Sisay N, Cantorias M, Zambre A, McLaughlin M, Kelsey J, Upenandran A, Robertson D, Deutscher S, Kannan R, Katti K.

Recent Results Cancer Res. 2013;194:133-47. doi: 10.1007/978-3-642-27994-2_8. Review.

PMID:
22918758
16.

Treatment-independent miRNA signature in blood of Wilms tumor patients.

Schmitt J, Backes C, Nourkami-Tutdibi N, Leidinger P, Deutscher S, Beier M, Gessler M, Graf N, Lenhof HP, Keller A, Meese E.

BMC Genomics. 2012 Aug 7;13:379. doi: 10.1186/1471-2164-13-379.

17.

Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.

Newton-Northup JR, Dickerson MT, Ma L, Besch-Williford CL, Deutscher SL.

Clin Exp Metastasis. 2013 Feb;30(2):119-32. doi: 10.1007/s10585-012-9516-y. Epub 2012 Aug 1.

PMID:
22851004
18.

A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.

Calzada V, Zhang X, Fernandez M, Diaz-Miqueli A, Iznaga-Escobar N, Deutscher SL, Balter H, Quinn TP, Cabral P.

Curr Radiopharm. 2012 Oct;5(4):318-24.

PMID:
22280117
19.

(64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen.

Kumar SR, Gallazzi FA, Quinn TP, Deutscher SL.

J Nucl Med. 2011 Nov;52(11):1819-26. doi: 10.2967/jnumed.111.093716. Epub 2011 Oct 7.

20.

Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model.

Gambini JP, Cabral P, Alonso O, Savio E, Figueroa SD, Zhang X, Ma L, Deutscher SL, Quinn TP.

Nucl Med Biol. 2011 Feb;38(2):255-60. doi: 10.1016/j.nucmedbio.2010.08.002. Epub 2010 Oct 27.

PMID:
21315281
21.

In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Kumar SR, Gallazzi FA, Ferdani R, Anderson CJ, Quinn TP, Deutscher SL.

Cancer Biother Radiopharm. 2010 Dec;25(6):693-703. doi: 10.1089/cbr.2010.0820.

22.

In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Deutscher SL, Figueroa SD, Kumar SR.

J Labelled Comp Radiopharm. 2009 Dec 1;52(14):583-590.

23.

Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.

Newton-Northup JR, Figueroa SD, Deutscher SL.

Comb Chem High Throughput Screen. 2011 Jan;14(1):9-21.

PMID:
20958260
24.

Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.

Deutscher SL, Dickerson M, Gui G, Newton J, Holm JE, Vogeltanz-Holm N, Kliethermes B, Hewett JE, Kumar SR, Quinn TP, Sauter ER.

BMC Cancer. 2010 Oct 1;10:519. doi: 10.1186/1471-2407-10-519.

25.

Phage display in molecular imaging and diagnosis of cancer.

Deutscher SL.

Chem Rev. 2010 May 12;110(5):3196-211. doi: 10.1021/cr900317f. Review. No abstract available.

26.

Bifunctional phage-based pretargeted imaging of human prostate carcinoma.

Newton-Northup JR, Figueroa SD, Quinn TP, Deutscher SL.

Nucl Med Biol. 2009 Oct;36(7):789-800. doi: 10.1016/j.nucmedbio.2009.04.010. Epub 2009 Jul 9.

27.

Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.

Deutscher SL, Figueroa SD, Kumar SR.

Nucl Med Biol. 2009 Feb;36(2):137-46. doi: 10.1016/j.nucmedbio.2008.10.015.

PMID:
19217525
28.

In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents.

Newton JR, Deutscher SL.

Methods Mol Biol. 2009;504:275-90. doi: 10.1007/978-1-60327-569-9_17.

PMID:
19159103
29.

Phage peptide display.

Newton J, Deutscher SL.

Handb Exp Pharmacol. 2008;(185 Pt 2):145-63. doi: 10.1007/978-3-540-77496-9_7. Review.

PMID:
18626602
30.

111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.

Kumar SR, Deutscher SL.

J Nucl Med. 2008 May;49(5):796-803. doi: 10.2967/jnumed.107.048751. Epub 2008 Apr 15.

31.

A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma.

Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, Urbschat S, Lenhof HP, Meese E.

Mol Cancer Res. 2008 Apr;6(4):576-84. doi: 10.1158/1541-7786.MCR-07-0283.

32.
33.

Melanoma imaging with pretargeted bivalent bacteriophage.

Newton JR, Miao Y, Deutscher SL, Quinn TP.

J Nucl Med. 2007 Mar;48(3):429-36.

34.

Specificity of phage display selected peptides for modified anticodon stem and loop domains of tRNA.

Eshete M, Marchbank MT, Deutscher SL, Sproat B, Leszczynska G, Malkiewicz A, Agris PF.

Protein J. 2007 Jan;26(1):61-73.

PMID:
17237992
35.

In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice.

Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL.

Neoplasia. 2006 Sep;8(9):772-80.

36.

Is phage display technology on target for developing peptide-based cancer drugs?

Landon LA, Zou J, Deutscher SL.

Curr Drug Discov Technol. 2004 Jun;1(2):113-32. Review.

PMID:
16472251
37.

Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection.

Kumar SR, Sauter ER, Quinn TP, Deutscher SL.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6868-71.

38.

Evidence for structural plasticity of heavy chain complementarity-determining region 3 in antibody-ssDNA recognition.

Schuermann JP, Prewitt SP, Davies C, Deutscher SL, Tanner JJ.

J Mol Biol. 2005 Apr 15;347(5):965-78.

PMID:
15784256
39.

Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.

Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL.

Carcinogenesis. 2005 Feb;26(2):309-18. Epub 2004 Nov 4.

PMID:
15528216
40.

Structure of an anti-DNA fab complexed with a non-DNA ligand provides insights into cross-reactivity and molecular mimicry.

Schuermann JP, Henzl MT, Deutscher SL, Tanner JJ.

Proteins. 2004 Nov 1;57(2):269-78.

PMID:
15340914
41.

Biodistribution of filamentous phage peptide libraries in mice.

Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL.

Mol Biol Rep. 2004 Jun;31(2):121-9.

PMID:
15293788
42.

High-throughput fluorescence spectroscopic analysis of affinity of peptides displayed on bacteriophage.

Landon LA, Harden W, Illy C, Deutscher SL.

Anal Biochem. 2004 Aug 1;331(1):60-7.

PMID:
15245997
43.

Effective combinatorial strategy to increase affinity of carbohydrate binding by peptides.

Landon LA, Zou J, Deutscher SL.

Mol Divers. 2004;8(1):35-50.

PMID:
14964786
44.

Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium.

Glinskii OV, Huxley VH, Turk JR, Deutscher SL, Quinn TP, Pienta KJ, Glinsky VV.

Clin Exp Metastasis. 2003;20(5):451-8.

45.

Combinatorial discovery of tumor targeting peptides using phage display.

Landon LA, Deutscher SL.

J Cell Biochem. 2003 Oct 15;90(3):509-17.

PMID:
14523985
46.

Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses.

Meighan MA, Dickerson MT, Glinskii O, Glinsky VV, Wright GL Jr, Deutscher SL.

J Protein Chem. 2003 May;22(4):317-26.

PMID:
13678295
47.

Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium.

Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP.

Cancer Res. 2003 Jul 1;63(13):3805-11.

48.

Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen.

Landon LA, Peletskaya EN, Glinsky VV, Karasseva N, Quinn TP, Deutscher SL.

J Protein Chem. 2003 Feb;22(2):193-204.

PMID:
12760424
49.

Crystal structure of an antigen-binding fragment bound to single-stranded DNA.

Tanner JJ, Komissarov AA, Deutscher SL.

J Mol Biol. 2001 Dec 7;314(4):807-22.

PMID:
11733999
50.

The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium.

Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP.

Cancer Res. 2001 Jun 15;61(12):4851-7.

Supplemental Content

Loading ...
Support Center